News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neurogen Says Insomnia Drug Safe In Phase I Trial
December 8, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dec 8 (Reuters) - Neurogen Corp. (NRGN.O: Quote, Profile, Research) on Thursday said the results of its Phase I multiple ascending dose trial for insomnia drug NG2-73 showed that the compound was safe and well tolerated.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
MORE ON THIS TOPIC
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees
September 11, 2025
·
1 min read
·
Tristan Manalac
Immunology and inflammation
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
September 10, 2025
·
2 min read
·
Tristan Manalac
